Stellar Kinematics and Environment at z~0.8 in the LEGA-C Survey:Massive, Slow-Rotators are Built First in Overdense Environments

In this Letter, we investigate the impact of environment on integrated and spatially resolved stellar kinematics of a sample of massive, quiescent galaxies at intermediate redshift (0.6 < z < 1.0). For this analysis, we combine photometric and spectroscopic parameters from the UltraVISTA and Large Early Galaxy Astrophysics Census surveys in the COSMOS field and environmental measurements. We analyze the trends with overdensity (1+δ) on the rotational support of quiescent galaxies and find no universal trends at either fixed mass or fixed stellar velocity dispersion. This is consistent with previous studies of the local universe; rotational support of massive galaxies depends primarily on stellar mass. We highlight two populations of massive galaxies () that deviate from the average mass relation. First, the most massive galaxies in the most underdense regions ((1 + δ) ≤ 1) exhibit elevated rotational support. Similarly, at the highest masses () the range in rotational support is significant in all but the densest regions. This corresponds to an increasing slow-rotator fraction such that only galaxies in the densest environments ((1 + δ) ≥ 3.5) are primarily (90% ± 10%) slow rotators. This effect is not seen at fixed velocity dispersion, suggesting minor merging as the driving mechanism: Only in the densest regions have the most massive galaxies experienced significant minor merging, building stellar mass and diminishing rotation without significantly affecting the central stellar velocity dispersion. In the local universe, most massive galaxies are slow rotators, regardless of environment, suggesting minor merging occurs at later cosmic times (z ≲ 0.6) in all but the most dense environments

The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study

[Background] Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm arising from the synovium of joints, bursae, and tendon sheaths affecting small and large joints. It represents a wide spectrum ranging from minimally symptomatic to massively debilitating. Most findings to date are mainly from small, retrospective case series, and thus the morbidity and actual impact of this rare disease remain to be elucidated. This study prospectively explores the management of TGCT in tertiary sarcoma centers.[Methods] The TGCT Observational Platform Project registry was a multinational, multicenter, prospective observational study involving 12 tertiary sarcoma centers in 7 European countries, and 2 US sites. This study enrolled for 2 years all consecutive ≥ 18 years old patients, with histologically diagnosed primary or recurrent cases of diffuse-type TGCT. Patient demographic and clinical characteristics were collected at baseline and every 6 months for 24 months. Quality of life questionnaires (PROMIS-PF and EQ-5D) were also administered at the same time-points. Here we report baseline patient characteristics.[Results] 166 patients were enrolled between November 2016 and March 2019. Baseline characteristics were: mean age 44 years (mean age at disease onset: 39 years), 139/166 (83.7%) had prior treatment, 71/166 patients (42.8%) had ≥ 1 recurrence after treatment of their primary tumor, 76/136 (55.9%) visited a medical specialist ≥ 5 times, 66/116 (56.9%) missed work in the 24 months prior to baseline, and 17/166 (11.6%) changed employment status or retired prematurely due to disease burden. Prior treatment consisted of surgery (i.e., arthroscopic, open synovectomy) (128/166; 77.1%) and systemic treatments (52/166; 31.3%) with imatinib (19/52; 36.5%) or pexidartinib (27/52; 51.9%). Treatment strategies at baseline visits consisted mainly of watchful waiting (81/166; 48.8%), surgery (41/166; 24.7%), or targeted systemic therapy (37/166; 22.3%). Patients indicated for treatment reported more impairment compared to patients indicated for watchful waiting: worst stiffness NRS 5.16/3.44, worst pain NRS 6.13/5.03, PROMIS-PF 39.48/43.85, and EQ-5D VAS 66.54/71.85.[Conclusion] This study confirms that diffuse-type TGCT can highly impact quality of life. A prospective observational registry in rare disease is feasible and can be a tool to collect curated-population reflective data in orphan diseases.[Name of registry] Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project (TOPP).[Trial registration number] NCT02948088.[Date of registration] 10 October 2016.[URL of Trial registry record] https://clinicaltrials.gov/ct2/show/NCT02948088?term=NCT02948088&draw=2.Sponsored by Daiichi Sankyo, Co., Ltd; ClinicalTrials.gov Number NCT02948088. The Department of Orthopaedics of the Leiden University Medical Center receives research funding from Daiichi Sankyo. All research funding for Memorial Sloan Kettering is supported in part by a grant from the National Institutes of Health/National Cancer Institute (#P30 CA008748).Peer reviewe

Association between short-term structured risk assessment outcomes and seclusion

ABSTRACT

Expandable distal femur megaprosthesis : a European Musculoskeletal Oncology Society study on 299 cases

Background and Objectives Expandable distal femur prostheses have become more popular over the last decades, but scientific data is limited. Methods A retrospective study was performed, including cases treated between 1986 and 2019 in 15 European referral centers for bone sarcomas. Results A total of 299 cases were included. Average follow-up was 80 months (range, 8-287 months). Mean patient age was 10 years. Most (80%) of the implants were noninvasive growers and a fixed hinge knee was used more often (64%) than a rotating hinge. Most prosthetic designs showed good (>80%) implant survival at 10 years, but repeat surgery was required for 63% of the patients. The most frequent reason for revision procedure was the completion of lengthening potential. Noninvasive expandable implants showed less risk of infection compared to invasive growers (11.8% vs 22.9% at 10 years). No difference in aseptic loosening was found between cemented and uncemented stems. Conclusions This study shows the increasing popularity of expandable distal femur prostheses, with overall good results for function and implant survival. However, repeat surgery is frequently required, especially in patients under the age of 10 years old. Infection is less frequent in noninvasive growers compared to implants that require invasive lengthening procedures

Different higher order kinematics between star-forming and quiescent galaxies based on the SAMI, MAGPI, and LEGA-C surveys

We present the first statistical study of spatially integrated non-Gaussian stellar kinematics spanning 7 Gyr in cosmic time. We use deep, rest-frame optical spectroscopy of massive galaxies (stellar mass ⁠) at redshifts z = 0.05, 0.3, and 0.8 from the SAMI, MAGPI, and LEGA-C surveys, to measure the excess kurtosis h4 of the stellar velocity distribution, the latter parametrized as a Gauss–Hermite series. We find that at all redshifts where we have large enough samples, h4 anticorrelates with the ratio between rotation and dispersion, highlighting the physical connection between these two kinematic observables. In addition, and independently from the anticorrelation with rotation-to-dispersion ratio, we also find a correlation between h4 and M⋆, potentially connected to the assembly history of galaxies. In contrast, after controlling for mass, we find no evidence of independent correlation between h4 and aperture velocity dispersion or galaxy size. These results hold for both star-forming and quiescent galaxies. For quiescent galaxies, h4 also correlates with projected shape, even after controlling for the rotation-to-dispersion ratio. At any given redshift, star-forming galaxies have lower h4 compared to quiescent galaxies, highlighting the link between kinematic structure and star-forming activity

Evolution in the orbital structure of quiescent galaxies from MAGPI, LEGA-C, and SAMI surveys: direct evidence for merger-driven growth over the last 7 Gyr

We present the first study of spatially integrated higher-order stellar kinematics over cosmic time. We use deep rest-frame optical spectroscopy of quiescent galaxies at redshifts z = 0.05, 0.3, and 0.8 from the SAMI, MAGPI, and LEGA-C surveys to measure the excess kurtosis h4 of the stellar velocity distribution, the latter parametrized as a Gauss-Hermite series. Conservatively using a redshift-independent cut in stellar mass (⁠⁠) and matching the stellar-mass distributions of our samples, we find 7σ evidence of h4 increasing with cosmic time, from a median value of 0.019 ± 0.002 at z = 0.8 to 0.059 ± 0.004 at z = 0.06. Alternatively, we use a physically motivated sample selection based on the mass distribution of the progenitors of local quiescent galaxies as inferred from numerical simulations; in this case, we find 10σ evidence. This evolution suggests that, over the last 7 Gyr, there has been a gradual decrease in the rotation-to-dispersion ratio and an increase in the radial anisotropy of the stellar velocity distribution, qualitatively consistent with accretion of gas-poor satellites. These findings demonstrate that massive galaxies continue to accrete mass and increase their dispersion support after becoming quiescent

1D Kinematics from stars and ionized gas at z∼0.8z\sim0.8 from the LEGA-C spectroscopic survey of massive galaxies

We present a comparison of the observed, spatially integrated stellar and ionized gas velocity dispersions of ~1000 massive ($\mathrm{log}\,{M}_{\star }/{M}_{\odot }\gtrsim 10.3$) galaxies in the Large Early Galaxy Astrophysics Census survey at 0.6 lesssim z lesssim 1.0. The high S/N ~ 20 Å−1 afforded by 20 hr Very Large Telescope/Visible Multi-Object Spectrograph spectra allows for joint modeling of the stellar continuum and emission lines in all galaxies, spanning the full range of galaxy colors and morphologies. These observed integrated velocity dispersions (denoted as ${\sigma }_{g,\mathrm{int}}^{{\prime} }$ and ${\sigma }_{\star ,\mathrm{int}}^{{\prime} }$) are related to the intrinsic velocity dispersions of ionized gas or stars, but also include rotational motions through beam smearing and spectral extraction. We find good average agreement between observed velocity dispersions, with $\langle \mathrm{log}({\sigma }_{g,\mathrm{int}}^{{\prime} }/{\sigma }_{\star ,\mathrm{int}}^{{\prime} })\rangle =-0.003$. This result does not depend strongly on stellar population, structural properties, or alignment with respect to the slit. However, in all regimes we find significant scatter between ${\sigma }_{g,\mathrm{int}}^{{\prime} }$ and ${\sigma }_{\star ,\mathrm{int}}^{{\prime} }$, with an overall scatter of 0.13 dex of which 0.05 dex is due to observational uncertainties. For an individual galaxy, the scatter between ${\sigma }_{g,\mathrm{int}}^{{\prime} }$ and ${\sigma }_{\star ,\mathrm{int}}^{{\prime} }$ translates to an additional uncertainty of ~0.24 dex on dynamical mass derived from ${\sigma }_{g,\mathrm{int}}^{{\prime} }$, on top of measurement errors and uncertainties from Virial constant or size estimates. We measure the z ~ 0.8 stellar mass Faber–Jackson relation and demonstrate that emission line widths can be used to measure scaling relations. However, these relations will exhibit increased scatter and slopes that are artificially steepened by selecting on subsets of galaxies with progressively brighter emission lines

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis:Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors

Objective: To investigate the efficacy and safety of ixekizumab in patients with active radiographic axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 tumor necrosis factor inhibitors (TNFi). Methods: In this phase III randomized, double-blind, placebo-controlled trial, adult patients with an inadequate response to or intolerance of 1 or 2 TNFi and an established diagnosis of axial SpA (according to the Assessment of SpondyloArthritis international Society [ASAS] criteria for radiographic axial SpA, with radiographic sacroiliitis defined according to the modified New York criteria and ≥1 feature of SpA) were recruited and randomized 1:1:1 to receive placebo or 80-mg subcutaneous ixekizumab every 2 weeks (IXEQ2W) or 4 weeks (IXEQ4W), with an 80-mg or 160-mg starting dose. The primary end point was 40% improvement in disease activity according to the ASAS criteria (ASAS40) at week 16. Secondary outcomes and safety were also assessed. Results: A total of 316 patients were randomized to receive placebo (n = 104), IXEQ2W (n = 98), or IXEQ4W (n = 114). At week 16, significantly higher proportions of IXEQ2W patients (n = 30 [30.6%]; P = 0.003) or IXEQ4W patients (n = 29 [25.4%]; P = 0.017) had achieved an ASAS40 response versus the placebo group (n = 13 [12.5%]), with statistically significant differences reported as early as week 1 with ixekizumab treatment. Statistically significant improvements in disease activity, function, quality of life, and spinal magnetic resonance imaging–evident inflammation were observed after 16 weeks of ixekizumab treatment versus placebo. Treatment-emergent adverse events (AEs) with ixekizumab treatment were more frequent than with placebo. Serious AEs were similar across treatment arms. One death was reported (IXEQ2W group). Conclusion: Ixekizumab treatment for 16 weeks in patients with active radiographic axial SpA and previous inadequate response to or intolerance of 1 or 2 TNFi yields rapid and significant improvements in the signs and symptoms of radiographic axial SpA versus placebo

Stellar Populations of over 1000 z ~ 0.8 Galaxies from LEGA-C:Ages and Star Formation Histories from D n 4000 and Hδ

Drawing from the LEGA-C dataset, we present the spectroscopic view of the stellar population across a large volume- and mass-selected sample of galaxies at large lookback time. We measure the 4000\AA\ break (D$_n$4000) and Balmer absorption line strengths (probed by H$\delta$) from 1019 high-quality spectra of $z=0.6 - 1.0$ galaxies with $M_\ast = 2 \times 10^{10} M_\odot - 3 \times 10^{11} M_\odot$. Our analysis serves as a first illustration of the power of high-resolution, high-S/N continuum spectroscopy at intermediate redshifts as a qualitatively new tool to constrain galaxy formation models. The observed D$_n$4000-EW(H$\delta$) distribution of our sample overlaps with the distribution traced by present-day galaxies, but $z\sim 0.8$ galaxies populate that locus in a fundamentally different manner. While old galaxies dominate the present-day population at all stellar masses $> 2\times10^{10} M_\odot$, we see a bimodal D$_n$4000-EW(H$\delta$) distribution at $z\sim0.8$, implying a bimodal light-weighted age distribution. The light-weighted age depends strongly on stellar mass, with the most massive galaxies $>1\times10^{11}M_\odot$ being almost all older than 2 Gyr. At the same time we estimate that galaxies in this high mass range are only $\sim3$ Gyr younger than their $z\sim0.1$ counterparts, at odd with pure passive evolution given a difference in lookback time of $>5$ Gyr; younger galaxies must grow to $>10^{11}M_\odot$ in the meantime, and/or small amounts of young stars must keep the light-weighted ages young. Star-forming galaxies at $z\sim0.8$ have stronger H$\delta$ absorption than present-day galaxies with the same D$_n$4000, implying larger short-term variations in star-formation activity